In the last few decades, in the field of Drug Discovery, Immunotherapy has gained more and more importance for the treatment of various diseases and in particular for certain types of cancer. Based on inducing, enhancing or suppressing an immune response, this therapeutic manipulation has led to promising clinical results.

Major regulators of Immune activation, Immune checkpoints play a key role in maintaining immune homoeostasis and preventing autoimmunity. However in some cancers, these checkpoints can be used to avoid any activation of the immune response against cancer cells. Immunotherapies based on targeting immune checkpoint pathways in Drug Discovery, have already led to the development of promising molecules (Nivolumab, Pembrolizumab…) tested in clinical trials and approved, which are giving new hope for cancer treatments.